147 related articles for article (PubMed ID: 27989824)
41. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
42. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
43. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
44. 4-methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis.
Piccioni F; Fiore E; Bayo J; Atorrasagasti C; Peixoto E; Rizzo M; Malvicini M; Tirado-González I; García MG; Alaniz L; Mazzolini G
Glycobiology; 2015 Aug; 25(8):825-35. PubMed ID: 25882295
[TBL] [Abstract][Full Text] [Related]
45. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
46. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
47. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth.
Yang WL; Wei L; Huang WQ; Li R; Shen WY; Liu JY; Xu JM; Li B; Qin Y
Oncol Rep; 2014 May; 31(5):2328-34. PubMed ID: 24676454
[TBL] [Abstract][Full Text] [Related]
48. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
Huang IT; Dhungel B; Shrestha R; Bridle KR; Crawford DHG; Jayachandran A; Steel JC
Expert Opin Investig Drugs; 2019 Jan; 28(1):7-18. PubMed ID: 30474444
[TBL] [Abstract][Full Text] [Related]
49. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
50. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma.
Chen G; Wang Y; Zhou M; Shi H; Yu Z; Zhu Y; Yu F
Oncol Rep; 2010 Feb; 23(2):563-70. PubMed ID: 20043122
[TBL] [Abstract][Full Text] [Related]
51. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
52. Saringosterol acetate isolated from Hizikia fusiforme, an edible brown alga, suppressed hepatocellular carcinoma growth and metastasis in a zebrafish xenograft model.
Kim EA; Lee JH; Heo SJ; Jeon YJ
Chem Biol Interact; 2021 Feb; 335():109362. PubMed ID: 33358999
[TBL] [Abstract][Full Text] [Related]
53. Zebrafish Xenotransplantation Models for Studying Gene Function and Drug Treatment in Hepatocellular Carcinoma.
Targen S; Konu O
J Gastrointest Cancer; 2021 Dec; 52(4):1248-1265. PubMed ID: 35031971
[TBL] [Abstract][Full Text] [Related]
54. Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.
Dai LC; Wang X; Yao X; Lu YL; Ping JL; He JF
World J Gastroenterol; 2007 Feb; 13(8):1208-13. PubMed ID: 17451201
[TBL] [Abstract][Full Text] [Related]
55. Inhibitory effects of bortezomib in a subcutaneous tumor model of H22 mouse hepatocarcinoma cells.
Zhu M
Pathol Res Pract; 2019 Jun; 215(6):152388. PubMed ID: 30914235
[TBL] [Abstract][Full Text] [Related]
56. Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment.
Wang L; Chen H; Fei F; He X; Sun S; Lv K; Yu B; Long J; Wang X
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31107449
[TBL] [Abstract][Full Text] [Related]
57. A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green.
Inagaki Y; Kokudo T; Kamiya M; Uno SN; Sato M; Kaneko J; Kokudo N; Urano Y; Hasegawa K
Sci Rep; 2019 Feb; 9(1):3044. PubMed ID: 30816163
[TBL] [Abstract][Full Text] [Related]
58. Fluorescent Imaging-Guided Chemo- and Photodynamic Therapy of Hepatocellular Carcinoma with HCPT@NMOFs-RGD Nanocomposites.
Shang Y; Zhang H; Cheng Y; Cao P; Cui J; Yin X; Fan S; Li Y
Int J Nanomedicine; 2022; 17():1381-1395. PubMed ID: 35369034
[TBL] [Abstract][Full Text] [Related]
59. Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules.
Tonon F; Farra R; Zennaro C; Pozzato G; Truong N; Parisi S; Rizzolio F; Grassi M; Scaggiante B; Zanconati F; Bonazza D; Grassi G; Dapas B
Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451900
[TBL] [Abstract][Full Text] [Related]
60. Animal models for hepatocellular carcinoma.
Zhang HE; Henderson JM; Gorrell MD
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):993-1002. PubMed ID: 31007176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
